DURHAM, N.C. (PRWEB) June 15, 2018
Entegrion, Inc. today announced that its VCM Vet viscoelastic coagulation testing platform is now commercially available to all North American animal health and science customers. The VCM Vet offers the benefits of viscoelastic testing in a low cost, fully automatic, highly accurate point of care coagulation device. Using a few drops of whole blood, a veterinarian can now gain a global understanding of a patient’s coagulation state to include: time to clot, rate of clotting, strength of clot and clot lysis. “The opportunity to bring viscoelastic testing to the veterinary market and its use on a daily basis will change medicine as we know it today,” said John Gicking, a critical care veterinarian. “Heatstroke, trauma, snakebites are just a few of the areas that will benefit from the additional information we will have now that the VCM Vet is available to us.”
The use of the VCM Vet in certain leading veterinary practices around the United States for more than a year prior to the system’s commercial introduction has demonstrated its reliability, quality in results and flexibility in use by the many different operators using the system. “We are pleased with the enthusiastic reception of Entegrion’s viscoelastic coagulation testing solution by many veterinary medicine professionals, and we look forward to supporting this critical diagnostic offering in animal health,” said John B. Mowell, Executive Chairman of Entegrion.
Viscoelastic testing has long been recognized as a valuable diagnostic tool in assessing both hypocoagulablity and hypercoagulability in patients.
Entegrion is a privately held life sciences company providing innovative solutions for clinical diagnosis and management of hemostasis. Our products bring about major changes to the critical pathways in the diagnosis and treatment of patient coagulopathies, enabling clinicians to rapidly and effectively advance care in both the hospital and field environments.